Investigational Drug Information for Milademetan

What is the drug development status for Milademetan?

Milademetan is an investigational drug.

There have been 12 clinical trials for Milademetan. The most recent clinical trial was a Phase 1 trial, which was initiated on July 14^th 2021.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Daiichi Sankyo, Inc., Rain Oncology Inc, and Daiichi Sankyo Inc.

There are fifty-one US patents protecting this investigational drug and ninety-eight international patents.

Summary for Milademetan

US Patents	51
International Patents	98
US Patent Applications	159
WIPO Patent Applications	111
Japanese Patent Applications	2
Clinical Trial Progress	Phase 1 (2021-07-14)
Vendors	35

Recent Clinical Trials for Milademetan

Title	Sponsor	Phase
Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer	Rain Oncology Inc	Phase 2
Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer	Institut Curie	Phase 2
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss	Rain Oncology Inc	Phase 1/Phase 2

See all Milademetan clinical trials

Clinical Trial Summary for Milademetan

Top disease conditions for Milademetan

Top clinical trial sponsors for Milademetan

See all Milademetan clinical trials

US Patents for Milademetan

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Milademetan		Crystals of dispiropyrrolidine derivatives	Daiichi Sankyo Company, Limited (Tokyo, JP)
Milademetan		Method for producing a spirooxindole derivative	Daiichi Sankyo Co Ltd
Milademetan		Crystals of dispiropyrrolidine derivatives	Daiichi Sankyo Company, Limited (Tokyo, JP)
Milademetan		Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors	Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Milademetan		Method for treating cancer by combined use	DAIICHI SANKYO COMPANY, LIMITED (Tokyo, JP)

International Patents for Milademetan

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Milademetan	Brazil	BR112015004816	2032-09-06
Milademetan	Canada	CA2884238	2032-09-06
Milademetan	China	CN104812757	2032-09-06
Milademetan	European Patent Office	EP2894156	2032-09-06
Milademetan	Spain	ES2637150	2032-09-06

Development Update and Market Projection for Milademetan

Last updated: February 13, 2026

Development Status

Milademetan (DS-6157) is an oral MDM2 inhibitor developed by Daiichi Sankyo for the treatment of certain cancers, notably advanced solid tumors and liposarcomas. As of Q4 2023, the drug is in late-stage clinical development.

• Clinical Trials:

  • Phase 1: Completed safety, dosing, and tolerability assessments; demonstrated manageable adverse events and preliminary antitumor activity.
  • Phase 2: Ongoing, with indications including LIC (leiomyosarcoma, liposarcoma), and other solid tumors. Daiichi Sankyo reports initial efficacy signals supported by durable responses in subsets of patients.
  • Trial Emphasis: Focuses on dose expansion and biomarker-driven patient selection. Recruitment is steady, with enrollment targets met in most trials.

• Regulatory Status:

  • No filings for approval submitted yet.
  • Discussions with the FDA suggest potential for breakthrough therapy designation based on early efficacy signals and disease unmet need.

• Manufacturing & Supply:

  • Daiichi Sankyo has scaled up manufacturing to support ongoing trials and potential commercialization.
  • No significant supply chain issues reported.

Market Landscape

• Competitive Pipeline:

  • MDM2 inhibitors under development by firms like Novartis, Roche, and Genentech. Notable candidates include RG7112 and SAR405838.
  • Few competitors have advanced beyond early phases.

• Current Approved Treatments:

  • No approved MDM2 inhibitors; conventional chemotherapies and targeted treatments dominate.
  • Liposarcomas, especially dedifferentiated subtypes, have limited targeted therapy options, creating potential market openings.

• Market Size and Revenue Potential:

  • Current Market: Soft tissue sarcomas, including liposarcoma, market valued at approximately $1.8 billion globally in 2022, projected to grow at 4% CAGR through 2027 (IQVIA).
  • Milademetan's Addressable Market:
  • Liposarcoma subtypes constitute roughly 20% of soft tissue sarcomas, translating to a taxable market of about $360 million.
  • Broader indications, including other solid tumors with p53 pathway dysregulation, could expand the addressable market to over $1 billion over several years post-approval.

Market Adoption Factors

• Biomarker-Driven Selection:

  • High p53 mutation frequency and MDM2 overexpression in target tumors enhance response likelihood.
  • Companion diagnostics may be developed to identify responders, improving clinical trial outcomes and post-approval adoption.

• Pricing and Reimbursement:

  • Anticipate premium pricing for targeted oral therapies with demonstrated efficacy in hard-to-treat populations.
  • Payer resistance could delay adoption unless early data convincingly shows improved survival or quality of life.

• Regulatory and Commercial Milestones:

  • Approval could occur in 2025 if phase 2 results are positive.
  • Market launch projected for late 2025 or early 2026, contingent on approval timelines and manufacturing readiness.

Risks and Considerations

• Clinical Risks:

  • Potential for adverse events related to MDM2 inhibition, such as hematologic toxicities.
  • Efficacy may be limited to select molecular profiles, restricting market penetration.

• Competitive Risks:

  • Novartis’ RG7112 in early Phase 2; if successful, could challenge Milademetan’s market position.
  • Future breakthroughs in immunotherapy might shift treatment paradigms.

Summary

Milademetan remains in late-phase clinical trials with promising early safety and efficacy signals, especially in liposarcoma. The current global soft tissue sarcoma market, valued at approximately $1.8 billion, presents a sizable opportunity if the drug gains regulatory approval. Competitive landscape is nascent but potentially intensifies as other MDM2 inhibitors advance. The company expects potential approval and market entry within the 2025–2026 window, driven by unmet medical needs and biomarker-driven selection strategies.

---

Key Takeaways

• Milademetan is in late-stage trials for liposarcoma and other solid tumors; regulatory submission may occur in 2024, with approval in 2025–2026.
• The targeted market could exceed $1 billion, driven by the soft tissue sarcoma segment and expanding indications.
• Competing drugs are mostly in early development; Milademetan’s success depends on demonstrating clear clinical advantages.
• Market adoption hinges on biomarker development, pricing strategies, and favorable regulatory decisions.
• Clinical, regulatory, and competitive risks remain significant, requiring close monitoring of trial results.

---

FAQs

1. What are the key indications for Milademetan?
   Liposarcoma (especially dedifferentiated subtypes), with potential expansion to other p53 pathway-related tumors.

2. When might Milademetan receive regulatory approval?
   In 2025 or early 2026, contingent on phase 2 trial outcomes and regulatory review.

3. How does Milademetan compare to other MDM2 inhibitors?
   It is among the most advanced in late-stage trials, with some competitors still in early phases, but efficacy and safety profiles must be confirmed.

4. What is the main clinical challenge for Milademetan?
   Managing toxicities and demonstrating significant clinical benefit over existing options.

5. What factors could influence its market success?
   Efficacy in biomarker-selected populations, regulatory approval timing, pricing strategy, and the competitive landscape.

---

Citations

1. IQVIA Market Reports 2022.
2. Daiichi Sankyo Corporate Updates, Q4 2023.
3. ClinicalTrials.gov Database, accessed January 2023.
4. Analyze Pharma Market Projections, 2022–2027.
5. FDA Discussions and Press Releases, 2023.